 Christina Nelson
Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lyme Disease | 18 | 2024 | 53 | 7.080 |
Why?
| | Plague | 14 | 2023 | 57 | 6.880 |
Why?
| | Tularemia | 12 | 2024 | 28 | 6.720 |
Why?
| | Francisella tularensis | 11 | 2024 | 30 | 6.230 |
Why?
| | Yersinia pestis | 9 | 2023 | 43 | 5.150 |
Why?
| | Anti-Infective Agents | 4 | 2024 | 246 | 1.660 |
Why?
| | Meningitis | 2 | 2024 | 81 | 1.550 |
Why?
| | Tick-Borne Diseases | 5 | 2021 | 9 | 1.490 |
Why?
| | Cat-Scratch Disease | 2 | 2020 | 2 | 1.250 |
Why?
| | Borrelia burgdorferi | 4 | 2021 | 16 | 1.140 |
Why?
| | Zoonoses | 4 | 2024 | 28 | 1.040 |
Why?
| | Tick Bites | 3 | 2021 | 4 | 0.920 |
Why?
| | Aminoglycosides | 4 | 2024 | 22 | 0.880 |
Why?
| | Occupational Exposure | 3 | 2024 | 312 | 0.840 |
Why?
| | Ticks | 3 | 2018 | 19 | 0.820 |
Why?
| | Organ Transplantation | 2 | 2019 | 225 | 0.810 |
Why?
| | Strigiformes | 1 | 2022 | 2 | 0.790 |
Why?
| | Anti-Bacterial Agents | 10 | 2024 | 1701 | 0.790 |
Why?
| | Coinfection | 1 | 2023 | 130 | 0.770 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2021 | 7 | 0.750 |
Why?
| | Nurse Practitioners | 1 | 2023 | 126 | 0.750 |
Why?
| | Bioterrorism | 5 | 2021 | 24 | 0.720 |
Why?
| | Bartonella henselae | 1 | 2020 | 1 | 0.710 |
Why?
| | Chorioretinitis | 1 | 2020 | 3 | 0.710 |
Why?
| | Incidence | 11 | 2024 | 2634 | 0.700 |
Why?
| | Retinitis | 1 | 2020 | 19 | 0.700 |
Why?
| | Humans | 57 | 2024 | 128896 | 0.660 |
Why?
| | Diagnostic Errors | 2 | 2018 | 163 | 0.650 |
Why?
| | Ixodes | 2 | 2016 | 13 | 0.650 |
Why?
| | Hospital Costs | 1 | 2020 | 117 | 0.650 |
Why?
| | Government Employees | 1 | 2018 | 1 | 0.630 |
Why?
| | Tetracyclines | 3 | 2024 | 9 | 0.620 |
Why?
| | Parks, Recreational | 1 | 2018 | 10 | 0.620 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2021 | 201 | 0.620 |
Why?
| | United States | 19 | 2024 | 13975 | 0.620 |
Why?
| | Pets | 1 | 2018 | 25 | 0.620 |
Why?
| | Vaccines | 1 | 2023 | 403 | 0.590 |
Why?
| | Insurance, Health | 1 | 2020 | 269 | 0.580 |
Why?
| | Female | 38 | 2024 | 68162 | 0.540 |
Why?
| | Clothing | 1 | 2016 | 20 | 0.520 |
Why?
| | Syncope | 1 | 2016 | 49 | 0.510 |
Why?
| | Bradycardia | 1 | 2016 | 56 | 0.510 |
Why?
| | Male | 32 | 2024 | 63146 | 0.500 |
Why?
| | Infant | 12 | 2022 | 8994 | 0.470 |
Why?
| | Diagnostic Test Approval | 1 | 2014 | 2 | 0.460 |
Why?
| | Young Adult | 15 | 2021 | 12286 | 0.450 |
Why?
| | Seasons | 5 | 2024 | 502 | 0.440 |
Why?
| | Animals | 18 | 2024 | 34628 | 0.440 |
Why?
| | Hot Temperature | 1 | 2016 | 362 | 0.430 |
Why?
| | Dogs | 4 | 2024 | 372 | 0.420 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 184 | 0.410 |
Why?
| | Hodgkin Disease | 1 | 2015 | 136 | 0.410 |
Why?
| | Adult | 22 | 2024 | 35361 | 0.400 |
Why?
| | Zika Virus | 3 | 2018 | 76 | 0.400 |
Why?
| | Child | 15 | 2024 | 20824 | 0.390 |
Why?
| | Fluoroquinolones | 2 | 2024 | 45 | 0.390 |
Why?
| | Middle Aged | 19 | 2024 | 30977 | 0.380 |
Why?
| | Africa | 2 | 2023 | 96 | 0.380 |
Why?
| | Infant, Newborn | 9 | 2024 | 5704 | 0.380 |
Why?
| | Zika Virus Infection | 3 | 2018 | 101 | 0.380 |
Why?
| | Abortion, Spontaneous | 2 | 2024 | 97 | 0.370 |
Why?
| | Population Surveillance | 4 | 2021 | 428 | 0.360 |
Why?
| | Central Nervous System Diseases | 1 | 2011 | 68 | 0.360 |
Why?
| | Asphyxia Neonatorum | 1 | 2010 | 17 | 0.360 |
Why?
| | Clinical Competence | 1 | 2018 | 1020 | 0.350 |
Why?
| | Hospitalization | 1 | 2020 | 2080 | 0.350 |
Why?
| | Child, Preschool | 10 | 2020 | 10457 | 0.340 |
Why?
| | Immunocompromised Host | 1 | 2011 | 198 | 0.330 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 145 | 0.330 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2009 | 5 | 0.320 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1281 | 0.320 |
Why?
| | Peer Review, Research | 1 | 2009 | 40 | 0.310 |
Why?
| | Premature Birth | 2 | 2024 | 313 | 0.300 |
Why?
| | Resuscitation | 1 | 2010 | 244 | 0.300 |
Why?
| | Tuberculosis | 1 | 2011 | 271 | 0.300 |
Why?
| | Adolescent | 15 | 2020 | 20197 | 0.290 |
Why?
| | Dermatology | 1 | 2009 | 115 | 0.280 |
Why?
| | Disease Outbreaks | 3 | 2020 | 333 | 0.280 |
Why?
| | Sex Factors | 4 | 2017 | 1947 | 0.280 |
Why?
| | Guidelines as Topic | 1 | 2009 | 259 | 0.280 |
Why?
| | Age Factors | 5 | 2018 | 3133 | 0.270 |
Why?
| | Health Care Surveys | 2 | 2019 | 560 | 0.260 |
Why?
| | Influenza Vaccines | 1 | 2011 | 544 | 0.260 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1060 | 0.260 |
Why?
| | Aged | 14 | 2024 | 22035 | 0.240 |
Why?
| | Influenza, Human | 1 | 2011 | 603 | 0.240 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2017 | 334 | 0.240 |
Why?
| | Bartonella Infections | 2 | 2016 | 4 | 0.230 |
Why?
| | Bartonella | 2 | 2016 | 7 | 0.230 |
Why?
| | Ibogaine | 1 | 2024 | 1 | 0.230 |
Why?
| | Insect Repellents | 2 | 2021 | 5 | 0.230 |
Why?
| | Trench Fever | 1 | 2024 | 5 | 0.230 |
Why?
| | Bartonella quintana | 1 | 2024 | 5 | 0.230 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 47 | 0.220 |
Why?
| | Ciprofloxacin | 1 | 2024 | 30 | 0.220 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 42 | 0.220 |
Why?
| | Antibodies, Bacterial | 3 | 2019 | 137 | 0.220 |
Why?
| | History, 21st Century | 3 | 2024 | 182 | 0.210 |
Why?
| | Streptococcus | 1 | 2023 | 25 | 0.210 |
Why?
| | Abscess | 1 | 2024 | 73 | 0.210 |
Why?
| | Fever | 2 | 2022 | 301 | 0.210 |
Why?
| | Chloramphenicol | 1 | 2022 | 9 | 0.210 |
Why?
| | Public Health Surveillance | 3 | 2021 | 68 | 0.210 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7050 | 0.200 |
Why?
| | Wyoming | 2 | 2019 | 27 | 0.200 |
Why?
| | Autopsy | 1 | 2022 | 89 | 0.190 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2353 | 0.190 |
Why?
| | Nicotine | 1 | 2024 | 303 | 0.190 |
Why?
| | Receptors, Nicotinic | 1 | 2024 | 323 | 0.190 |
Why?
| | Dopamine | 1 | 2024 | 281 | 0.180 |
Why?
| | Insecticides | 1 | 2021 | 34 | 0.180 |
Why?
| | Dancing | 1 | 2020 | 14 | 0.180 |
Why?
| | Databases, Factual | 2 | 2016 | 1289 | 0.180 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 21 | 0.180 |
Why?
| | Insurance Claim Review | 1 | 2021 | 74 | 0.170 |
Why?
| | Pregnancy | 7 | 2024 | 6247 | 0.170 |
Why?
| | Asia | 1 | 2020 | 58 | 0.170 |
Why?
| | Gentamicins | 1 | 2020 | 51 | 0.170 |
Why?
| | Maryland | 1 | 2019 | 43 | 0.170 |
Why?
| | Virginia | 1 | 2019 | 59 | 0.160 |
Why?
| | Relapsing Fever | 1 | 2019 | 1 | 0.160 |
Why?
| | Caves | 1 | 2019 | 4 | 0.160 |
Why?
| | Dog Diseases | 1 | 2020 | 52 | 0.160 |
Why?
| | Sentinel Surveillance | 1 | 2019 | 40 | 0.160 |
Why?
| | Bites and Stings | 1 | 2018 | 32 | 0.150 |
Why?
| | Odds Ratio | 1 | 2021 | 1019 | 0.150 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 155 | 0.150 |
Why?
| | Vermont | 1 | 2018 | 5 | 0.150 |
Why?
| | Semen | 1 | 2018 | 19 | 0.150 |
Why?
| | Data Collection | 1 | 2021 | 652 | 0.150 |
Why?
| | Virus Shedding | 1 | 2018 | 44 | 0.150 |
Why?
| | Blood Donors | 1 | 2019 | 94 | 0.150 |
Why?
| | Postural Balance | 1 | 2020 | 208 | 0.150 |
Why?
| | Case-Control Studies | 2 | 2018 | 3334 | 0.150 |
Why?
| | Muscle Strength | 1 | 2020 | 305 | 0.140 |
Why?
| | Sciuridae | 1 | 2019 | 145 | 0.140 |
Why?
| | Biological Warfare | 1 | 2017 | 2 | 0.140 |
Why?
| | RNA, Viral | 2 | 2018 | 622 | 0.140 |
Why?
| | Clinical Laboratory Techniques | 1 | 2017 | 86 | 0.140 |
Why?
| | Manuals as Topic | 1 | 2016 | 14 | 0.140 |
Why?
| | HIV Infections | 1 | 2011 | 2696 | 0.140 |
Why?
| | Insurance Claim Reporting | 1 | 2016 | 23 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2668 | 0.130 |
Why?
| | Nymph | 1 | 2016 | 5 | 0.130 |
Why?
| | Tinea | 1 | 2016 | 2 | 0.130 |
Why?
| | Exercise Therapy | 1 | 2020 | 406 | 0.130 |
Why?
| | Pneumonia, Bacterial | 1 | 2017 | 112 | 0.130 |
Why?
| | Lymphatic Diseases | 1 | 2016 | 20 | 0.130 |
Why?
| | Humidity | 1 | 2016 | 50 | 0.130 |
Why?
| | Tissue Donors | 1 | 2019 | 398 | 0.130 |
Why?
| | Risk Factors | 6 | 2024 | 9792 | 0.130 |
Why?
| | Doxycycline | 1 | 2016 | 57 | 0.130 |
Why?
| | Administration, Topical | 1 | 2016 | 148 | 0.130 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 210 | 0.130 |
Why?
| | Immunoblotting | 1 | 2016 | 302 | 0.120 |
Why?
| | Laboratories | 1 | 2016 | 102 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2016 | 132 | 0.120 |
Why?
| | Public Health | 1 | 2020 | 493 | 0.120 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 30 | 0.120 |
Why?
| | Office Visits | 1 | 2015 | 85 | 0.120 |
Why?
| | Cross Infection | 1 | 2017 | 203 | 0.120 |
Why?
| | Disease Progression | 1 | 2022 | 2603 | 0.120 |
Why?
| | Bacterial Infections | 1 | 2017 | 236 | 0.120 |
Why?
| | Cold Temperature | 1 | 2016 | 150 | 0.120 |
Why?
| | Symptom Assessment | 1 | 2016 | 127 | 0.120 |
Why?
| | Culture Techniques | 1 | 2014 | 82 | 0.110 |
Why?
| | Cost of Illness | 1 | 2016 | 290 | 0.110 |
Why?
| | Nurses | 1 | 2016 | 163 | 0.110 |
Why?
| | Physicians, Primary Care | 1 | 2016 | 233 | 0.110 |
Why?
| | Myocarditis | 1 | 2014 | 101 | 0.110 |
Why?
| | Death, Sudden, Cardiac | 1 | 2014 | 179 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 204 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2017 | 479 | 0.100 |
Why?
| | Vaccination | 2 | 2012 | 1350 | 0.100 |
Why?
| | Water | 1 | 2016 | 441 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2019 | 713 | 0.100 |
Why?
| | Kidney Transplantation | 1 | 2019 | 638 | 0.100 |
Why?
| | Nurseries, Hospital | 1 | 2012 | 5 | 0.100 |
Why?
| | Outpatients | 1 | 2015 | 366 | 0.100 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 49 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5032 | 0.090 |
Why?
| | Hepatitis B | 1 | 2012 | 61 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1192 | 0.090 |
Why?
| | Nepal | 1 | 2010 | 21 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 5355 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2020 | 14546 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1629 | 0.090 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 41 | 0.090 |
Why?
| | Bacteremia | 1 | 2012 | 190 | 0.090 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2012 | 166 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2767 | 0.080 |
Why?
| | Health Policy | 1 | 2012 | 359 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1523 | 0.080 |
Why?
| | Interviews as Topic | 1 | 2010 | 696 | 0.070 |
Why?
| | Lung | 1 | 2020 | 3925 | 0.070 |
Why?
| | Colombia | 2 | 2017 | 37 | 0.070 |
Why?
| | Fatal Outcome | 2 | 2017 | 301 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3042 | 0.070 |
Why?
| | Sex Distribution | 2 | 2016 | 357 | 0.060 |
Why?
| | Colorado | 2 | 2012 | 4443 | 0.060 |
Why?
| | Nicotinic Antagonists | 1 | 2024 | 33 | 0.060 |
Why?
| | Xenopus laevis | 1 | 2024 | 99 | 0.060 |
Why?
| | Self Administration | 1 | 2024 | 126 | 0.050 |
Why?
| | Oocytes | 1 | 2024 | 178 | 0.050 |
Why?
| | Interneurons | 1 | 2024 | 115 | 0.050 |
Why?
| | Nicotinic Agonists | 1 | 2024 | 125 | 0.050 |
Why?
| | Nucleus Accumbens | 1 | 2024 | 128 | 0.050 |
Why?
| | Synaptic Transmission | 1 | 2024 | 258 | 0.050 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 39 | 0.040 |
Why?
| | Anorexia | 1 | 2020 | 19 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 273 | 0.040 |
Why?
| | Animals, Domestic | 1 | 2019 | 14 | 0.040 |
Why?
| | New Mexico | 1 | 2020 | 60 | 0.040 |
Why?
| | Random Allocation | 1 | 2020 | 351 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 1968 | 0.040 |
Why?
| | Permethrin | 1 | 2019 | 1 | 0.040 |
Why?
| | Motor Activity | 1 | 2024 | 666 | 0.040 |
Why?
| | Recreation | 1 | 2019 | 21 | 0.040 |
Why?
| | Medicare | 1 | 2024 | 734 | 0.040 |
Why?
| | Farmers | 1 | 2019 | 64 | 0.040 |
Why?
| | Arvicolinae | 1 | 2019 | 28 | 0.040 |
Why?
| | Texas | 1 | 2019 | 227 | 0.040 |
Why?
| | History, 20th Century | 1 | 2019 | 294 | 0.040 |
Why?
| | Arkansas | 1 | 2017 | 15 | 0.040 |
Why?
| | Arizona | 1 | 2017 | 78 | 0.040 |
Why?
| | Placenta | 1 | 2024 | 706 | 0.040 |
Why?
| | Glanders | 1 | 2017 | 1 | 0.040 |
Why?
| | Typhus, Epidemic Louse-Borne | 1 | 2017 | 1 | 0.040 |
Why?
| | Melioidosis | 1 | 2017 | 5 | 0.040 |
Why?
| | Biological Warfare Agents | 1 | 2017 | 3 | 0.040 |
Why?
| | Anthrax | 1 | 2017 | 9 | 0.030 |
Why?
| | Smallpox | 1 | 2017 | 8 | 0.030 |
Why?
| | Knee Joint | 1 | 2020 | 366 | 0.030 |
Why?
| | Botulism | 1 | 2017 | 6 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2017 | 113 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 326 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 10239 | 0.030 |
Why?
| | Geography, Medical | 1 | 2016 | 11 | 0.030 |
Why?
| | Serologic Tests | 1 | 2016 | 49 | 0.030 |
Why?
| | Georgia (Republic) | 1 | 2016 | 3 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 448 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2016 | 105 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 57 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 957 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 376 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5270 | 0.030 |
Why?
| | Health Surveys | 1 | 2015 | 485 | 0.030 |
Why?
| | Hepatitis B virus | 1 | 2012 | 34 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1840 | 0.020 |
Why?
| | Perinatal Care | 1 | 2012 | 54 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1715 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 544 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5236 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6568 | 0.020 |
Why?
| | Mice | 1 | 2024 | 16543 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7060 | 0.020 |
Why?
| | Risk Assessment | 1 | 2014 | 3286 | 0.010 |
Why?
|
|
Nelson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|